135 related articles for article (PubMed ID: 35279418)
1. Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With Metastatic Castration-Resistant Prostate Cancer.
Anand A; Heller G; Fox J; Danila DC; Bjartell A; Edenbrandt L; Larson SM; Scher HI; Morris MJ
Clin Genitourin Cancer; 2022 Jun; 20(3):270-277. PubMed ID: 35279418
[TBL] [Abstract][Full Text] [Related]
2. Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Armstrong AJ; Anand A; Edenbrandt L; Bondesson E; Bjartell A; Widmark A; Sternberg CN; Pili R; Tuvesson H; Nordle Ö; Carducci MA; Morris MJ
JAMA Oncol; 2018 Jul; 4(7):944-951. PubMed ID: 29799999
[TBL] [Abstract][Full Text] [Related]
3. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
Sonpavde G; Pond GR; Armstrong AJ; Galsky MD; Leopold L; Wood BA; Wang SL; Paolini J; Chen I; Chow-Maneval E; Mooney DJ; Lechuga M; Smith MR; Michaelson MD
BJU Int; 2014 Dec; 114(6b):E25-E31. PubMed ID: 24298897
[TBL] [Abstract][Full Text] [Related]
4. Assessing Radiographic Response to
Anand A; Trägårdh E; Edenbrandt L; Beckman L; Svensson JH; Thellenberg C; Widmark A; Kindblom J; Ullén A; Bjartell A
J Nucl Med; 2020 May; 61(5):671-675. PubMed ID: 31586004
[TBL] [Abstract][Full Text] [Related]
5. Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials.
Mota JM; Armstrong AJ; Larson SM; Fox JJ; Morris MJ
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):522-530. PubMed ID: 31036925
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel.
Uemura K; Miyoshi Y; Kawahara T; Ryosuke J; Yamashita D; Yoneyama S; Yokomizo Y; Kobayashi K; Kishida T; Yao M; Uemura H
BMC Cancer; 2018 May; 18(1):501. PubMed ID: 29716525
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
Armstrong AJ; Kaboteh R; Carducci MA; Damber JE; Stadler WM; Hansen M; Edenbrandt L; Forsberg G; Nordle Ö; Pili R; Morris MJ
Urol Oncol; 2014 Nov; 32(8):1308-16. PubMed ID: 25240761
[TBL] [Abstract][Full Text] [Related]
8. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial.
Kitajima K; Igeta M; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Narita M; Daimon T; Yamakado K
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1487-1498. PubMed ID: 36539508
[TBL] [Abstract][Full Text] [Related]
9. Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
McNamara MA; Oyekunle T; Chin BB; Oldan J; Anand A; Ritz M; Shantzer L; Anand M; Armstrong AJ; George DJ
Prostate; 2019 Jul; 79(10):1106-1116. PubMed ID: 31045266
[TBL] [Abstract][Full Text] [Related]
10. The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison".
Ali A; Hoyle AP; Parker CC; Brawley CD; Cook A; Amos C; Calvert J; Douis H; Mason MD; Attard G; Parmar MKB; Sydes MR; James ND; Clarke NW;
Eur Urol Oncol; 2020 Aug; 3(4):412-419. PubMed ID: 32591246
[TBL] [Abstract][Full Text] [Related]
11. Correlation between Automated Bone Scan Index Change after Cabazitaxel and Survival among Men with Castration-Resistant Prostate Cancer.
Miyoshi Y; Sakamoto S; Kawahara T; Uemura K; Yokomizo Y; Uemura H
Urol Int; 2019; 103(3):279-284. PubMed ID: 31461725
[TBL] [Abstract][Full Text] [Related]
12. Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11.
Reza M; Wirth M; Tammela T; Cicalese V; Veiga FG; Mulders P; Miller K; Tubaro A; Debruyne F; Patel A; Caris C; Witjes W; Thorsson O; Wollmer P; Edenbrandt L; Ohlsson M; Trägårdh E; Bjartell A
Eur Urol Oncol; 2021 Feb; 4(1):49-55. PubMed ID: 31186177
[TBL] [Abstract][Full Text] [Related]
13. Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients.
Woo S; Suh CH; Wibmer AG; Becker AS; Teo MY; Gönen M; Hricak H; Scher HI; Morris MJ; Vargas HA
Clin Genitourin Cancer; 2022 Feb; 20(1):69-79. PubMed ID: 34903480
[TBL] [Abstract][Full Text] [Related]
14. Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer.
Parker SJ; Pond GR; Agarwal N; Alex A; Heilbrun ME; Sonpavde G
Clin Genitourin Cancer; 2017 Feb; 15(1):53-59. PubMed ID: 27338517
[TBL] [Abstract][Full Text] [Related]
15. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.
Morris MJ; Molina A; Small EJ; de Bono JS; Logothetis CJ; Fizazi K; de Souza P; Kantoff PW; Higano CS; Li J; Kheoh T; Larson SM; Matheny SL; Naini V; Burzykowski T; Griffin TW; Scher HI; Ryan CJ
J Clin Oncol; 2015 Apr; 33(12):1356-63. PubMed ID: 25624432
[TBL] [Abstract][Full Text] [Related]
16. Expert System for Bone Scan Interpretation Improves Progression Assessment in Bone Metastatic Prostate Cancer.
Haupt F; Berding G; Namazian A; Wilke F; Böker A; Merseburger A; Geworski L; Kuczyk MA; Bengel FM; Peters I
Adv Ther; 2017 Apr; 34(4):986-994. PubMed ID: 28265811
[TBL] [Abstract][Full Text] [Related]
17. Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer.
Mitsui Y; Shiina H; Yamamoto Y; Haramoto M; Arichi N; Yasumoto H; Kitagaki H; Igawa M
BJU Int; 2012 Dec; 110(11 Pt B):E628-34. PubMed ID: 22788759
[TBL] [Abstract][Full Text] [Related]
18. Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer.
Saylor PJ; Otani K; Balza R; Ukleja J; Pleskow H; Fisher R; Kusaka E; Otani YS; Badusi PO; Smith MR; Meneely E; Olivier K; Lowe AC; Toner M; Maheswaran S; Haber DA; Yeap BY; Lee RJ; Miyamoto DT
JCO Precis Oncol; 2024 Feb; 8():e2300230. PubMed ID: 38354328
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of automated bone scan index for predicting overall survival among bone metastatic castration resistant prostate cancer patients treated with radium-223.
Miyoshi Y; Tsutsumi S; Kawahara T; Yasui M; Uemura K; Yoneyama S; Yokomizo Y; Hayashi N; Yao M; Uemura H
BJUI Compass; 2021 Jan; 2(1):24-30. PubMed ID: 35474664
[TBL] [Abstract][Full Text] [Related]
20. Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.
Sonpavde G; Pond GR; Templeton AJ; Fandi A; Tombal B; Rosenthal M; Armstrong AJ; Petrylak DP
Eur Urol; 2016 Jun; 69(6):980-3. PubMed ID: 26497922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
